"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

"The Obama administration is poised to spend a lot of money on infrastructure; one important sector is the the nation's electric power grid and the communications system," notes growth stock advisor Dave Dyer.

In his Dave Dayer's Newsletter, he explains, "Some products will win big, others will get nothing, but one company will get more business regardless of which products win: Quanta Services (NYSE: PWR), the leading electrical contractor in the country.

"Quanta's service business stands ready to expand with the infrastructure buildout no matter which products are selected.

"They do design, installation, maintenance, and repair on just about any type of network infrastructure (electric power, telecom, broadband cable, and gas pipelines.) Their moat against competitors is size. They are the largest in their field and that is in no danger of changing.

"The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer.

In The Dave Dyer Newsletter, he explains, "That is why Celgene (NASDAQ: CELG) is an excellent choice in this economy." Here's his look at this "recession-resistant" company.

"Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt. Revlimid is their blockbuster drug with multi-billion dollar potential. It was first approved by the FDA in 2005, and it has many good years of patent protection ahead of it.

"Revlimid delays the onset of progression of deadly diseases -- leprosy and multiple myeloma. No wonder it is worth $6,000 per month. It is a close derivative of their other drug Thalomid. This drug was used by another company about 50 years ago to treat morning sickness in pregnant women and caused numerous birth defects.

"Despite a recession, we believe that demand for its products will remain strong. For example, if you have multiple myeloma, you would probably do just about anything before missing a payment for your monthly dose of Revlimid.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Stericycle (NASDAQ: SRCL) is an almost perfect business -- an absolutely essential service, but nobody wants to do it," says Dave Dyer in his Dave Dyer's Newsletter, referring to his more conservative favorite for 2008.

"It is about as close to being a monopoly as you are likely to find, especially in a critical national industry. Stericycle is the acknowledged leader in the unglamorous but necessary task of medical waste disposal.

"It is 12 times bigger than its nearest rival and SRCL is the only vendor able to provide services on a nationwide basis, which means that the large, nationwide customers have only one good option unless they want to deal with multiple vendors.

"The highly regulated nature of its business acts as a convenient barrier to entry by potential competitors. And even if someone does manage to start a competing company, there is a good chance that SRCL will buy them.